XML 21 R10.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Balance Sheet Components | 3 Months Ended
--- | ---
Mar. 31, 2024
Balance Sheet Related Disclosures [Abstract] |
Balance Sheet Components | Balance Sheet Components Goodwill The changes in the carrying amounts of goodwill were as follows (in thousands of dollars):
| Amounts
Balance as of December 31, 2023 | $ | 702,984 |
Goodwill acquired - C2i | 55,974 |
Effect of foreign currency translation on Goodwill acquired - HalioDx | (5,105) |
Balance as of March 31, 2024 | $ | 753,853 |
Intangible Assets, Net Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):
| March 31, 2024 |  | December 31, 2023 |  | Weighted Average Remaining Amortization Period (Years)
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |  | Gross Carrying Amount |  | Accumulated Amortization |  | Net Carrying Amount |
Percepta product technology | $ | 16,000 |  |  | $ | (9,600) |  |  | $ | 6,400 |  |  | $ | 16,000 |  |  | $ | (9,333) |  |  | $ | 6,667 |  |  | 6
Prosigna product technology | 4,120 |  |  | (1,190) |  |  | 2,930 |  |  | 4,120 |  |  | (1,122) |  |  | 2,998 |  |  | 11
Prosigna customer relationships | 2,430 |  |  | (2,106) |  |  | 324 |  |  | 2,430 |  |  | (1,985) |  |  | 445 |  |  | 1
LymphMark product technology | 990 |  |  | (613) |  |  | 377 |  |  | 990 |  |  | (577) |  |  | 413 |  |  | 3
Decipher product technology | 90,000 |  |  | (27,484) |  |  | 62,516 |  |  | 90,000 |  |  | (25,234) |  |  | 64,766 |  |  | 7
Decipher trade names | 4,000 |  |  | (2,443) |  |  | 1,557 |  |  | 4,000 |  |  | (2,243) |  |  | 1,757 |  |  | 2
HalioDx developed technology | 1,404 |  |  | (374) |  |  | 1,030 |  |  | 1,435 |  |  | (346) |  |  | 1,089 |  |  | 7
HalioDx customer relationships | 2,699 |  |  | (1,436) |  |  | 1,263 |  |  | 2,760 |  |  | (1,331) |  |  | 1,429 |  |  | 2
HalioDx customer backlog | 4,166 |  |  | (2,734) |  |  | 1,432 |  |  | 4,258 |  |  | (2,529) |  |  | 1,729 |  |  | 1
C2i developed technology | 25,300 |  |  | (281) |  |  | 25,019 |  |  | — |  |  | — |  |  | — |  |  | 15
Total finite-lived intangibles | 151,109 |  |  | (48,261) |  |  | 102,848 |  |  | 125,993 |  |  | (44,700) |  |  | 81,293 |  |  | 8.7
In-process research and development | 13,500 |  |  | — |  |  | 13,500 |  |  | 7,300 |  |  | — |  |  | 7,300 |  |  |
Total intangible assets | $ | 164,609 |  |  | $ | (48,261) |  |  | $ | 116,348 |  |  | $ | 133,293 |  |  | $ | (44,700) |  |  | $ | 88,593 |  |  |
Acquisition-related intangibles are generally finite-lived and are carried at cost less accumulated amortization. Amortization of the finite-lived intangible assets is recognized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized. Amortization expense of $3.7 million and $5.3 million was recognized for the three months ended March 31, 2024 and 2023, respectively. The estimated future aggregate amortization expense as of March 31, 2024 is as follows (in thousands of dollars):
Year Ending December 31, | Amounts
2024 remainder of year | $ | 11,332 |
2025 | 14,250 |
2026 | 12,773 |
2027 | 12,169 |
2028 | 12,169 |
Thereafter | 40,155 |
Total | $ | 102,848 |
Impairment of Long-Lived Assets Impairment of long-lived assets for the three months ended March 31, 2024 and 2023 was $0.4 million and $1.4 million, respectively, of impairment of right-of-use and fixed assets in relation to exiting our Watertown and Richmond facilities. Supplies and Inventory As of March 31, 2024 and December 31, 2023, supplies and inventory consisted of $13.7 million and $12.2 million, respectively, of lab supplies and reagents consumed in the performance of testing services, and $4.6 million and $4.0 million, respectively, of inventory related to finished and semi-finished components used in the assembly of diagnostic kits related to product sales and raw materials consumed in the contract manufacturing process. Accrued Liabilities Accrued liabilities consisted of the following (in thousands of dollars):
| March 31, 2024 |  | December 31, 2023
Accrued compensation expenses | $ | 16,948 |  |  | $ | 26,430 |
Accrued other | 13,345 |  |  | 11,997 |
Total accrued liabilities | $ | 30,293 |  |  | $ | 38,427 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration